– USA, CA – Alumis, a precision immunology company that is reimagining the discovery, development, and treatment of autoimmune disorders, today announced the appointment of Dr. Sapna Srivastava (Ph.D.) a biotechnology and financial industry leader, to its board of directors.
“We are pleased to welcome Sapna to our board, whose demonstrated track record of leading successful business strategy and financial organizations across the biotechnology industry will be highly valuable to Alumis. Sapna’s industry experience, combined with her time spent on Wall Street, offers a unique perspective, and we look forward to partnering with her as we continue to advance our precision immunology programs,” said CEO Martin Babler.
About Dr. Sapna Srivastava
Dr. Srivastava is an experienced senior executive within the biopharmaceutical industry and Wall Street. Previously, Dr. Srivastava was the chief financial and strategy officer for Abide Therapeutics, and before that, was the chief financial and strategy officer for Intellia Therapeutics. She played an integral role in helping build Intellia’s financial operations and strategic direction, as well as the company’s Series B financing and its initial public offering. Before her industry experience, she spent nearly 15 years as a stock analyst for the biotechnology sector on Wall Street, including as the senior analyst and team leader of the biotechnology group at Goldman Sachs; a senior biotechnology analyst at Morgan Stanley and ThinkEquity Partners; and as a research associate at JP Morgan. Dr. Srivastava also has experience as an independent board member for several therapeutic-focused biotechnology companies and nonprofits.
“Through the combination of its precision analytics platform and a team with deep experience in immunology and successful drug development, Alumis has an opportunity to rewrite the way autoimmune diseases are treated,” said Dr. Srivastava. “I look forward to collaborating with the board and management team to advance the business and precision immunology pipeline.”
Dr. Srivastava holds a Ph.D. from New York University School of Medicine and a B.Sc. from St. Xavier’s College, University of Bombay.
About Alumis
Alumis is a precision immunology company looking to eliminate the “all-comer” approach that is seen with today’s treatments for people with autoimmune diseases. Even with innovations of the last decade, many patients continue to cycle through the approved therapies while continuing to look for the right therapy to alleviate the impact of their disease without life-impacting side effects. Alumis leverages a precision analytics platform, powered by Foresite Labs, coupled with a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that change the lives of people with autoimmune diseases.
For more information: https://www.alumis.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
